VYNE Therapeutics Inc.VYNENASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+1.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+1.0%/yr
Quarterly compound
Percentile
P95
Near historical high
vs 3Y Ago
1x
Modest growth
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 46.96% |
| Q3 2025 | 34.31% |
| Q2 2025 | 5.74% |
| Q1 2025 | -27.36% |
| Q4 2024 | -5.75% |
| Q3 2024 | -0.33% |
| Q2 2024 | -6.28% |
| Q1 2024 | -55.36% |
| Q4 2023 | 0.29% |
| Q3 2023 | 46.19% |
| Q2 2023 | -74.77% |
| Q1 2023 | -41.37% |
| Q4 2022 | 45.61% |
| Q3 2022 | 13.37% |
| Q2 2022 | 9.01% |
| Q1 2022 | 9.77% |
| Q4 2021 | 42.89% |
| Q3 2021 | -7.90% |
| Q2 2021 | -29.53% |
| Q1 2021 | 50.54% |
| Q4 2020 | -7.35% |
| Q3 2020 | 34.08% |
| Q2 2020 | 31.32% |
| Q1 2020 | -218.09% |
| Q4 2019 | -0.23% |
| Q3 2019 | -14.96% |
| Q2 2019 | 21.14% |
| Q1 2019 | -8.71% |
| Q4 2018 | -36.52% |
| Q3 2018 | 3.81% |
| Q2 2018 | -12.08% |
| Q1 2018 | -10.76% |
| Q4 2017 | 18.50% |
| Q3 2017 | -33902.70% |
| Q2 2017 | 100.66% |
| Q1 2017 | -22.75% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |